Zhang Huaiyuan, Wang Yu, Qiang Huifen, Leng Dewen, Yang Luling, Hu Xueneng, Chen Feiyan, Zhang Tinglin, Gao Jie, Yu Zuochong
Department of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Changhai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Mater Today Bio. 2024 Sep 29;29:101276. doi: 10.1016/j.mtbio.2024.101276. eCollection 2024 Dec.
The standard treatment for osteosarcoma combines surgery with chemotherapy, yet it is fraught with challenges such as postoperative tumor recurrence and chemotherapy-induced side effects. Additionally, bone defects after surgery often surpass the body's regenerative ability, affecting patient recovery. Bioengineering offers a novel approach through the use of bioactive scaffolds crafted from metals, ceramics, and hydrogels for bone defect repair. However, these scaffolds are typically devoid of antitumor properties, necessitating the integration of therapeutic agents. The development of a multifunctional therapeutic platform incorporating chemotherapeutic drugs, photothermal agents (PTAs), photosensitizers (PIs), sound sensitizers (SSs), magnetic thermotherapeutic agents (MTAs), and naturally occurring antitumor compounds addresses this limitation. This platform is engineered to target osteosarcoma cells while also facilitating bone tissue repair and regeneration. This review synthesizes recent advancements in integrated bioactive scaffolds (IBSs), underscoring their dual role in combating osteosarcoma and enhancing bone regeneration. We also examine the current limitations of IBSs and propose future research trajectories to overcome these hurdles.
骨肉瘤的标准治疗方法是手术联合化疗，但它充满了挑战，如术后肿瘤复发和化疗引起的副作用。此外，手术后的骨缺损往往超过身体的再生能力，影响患者康复。生物工程通过使用由金属、陶瓷和水凝胶制成的生物活性支架为骨缺损修复提供了一种新方法。然而，这些支架通常缺乏抗肿瘤特性，因此需要整合治疗剂。结合化疗药物、光热剂（PTA）、光敏剂（PI）、声敏剂（SS）、磁热治疗剂（MTA）和天然抗肿瘤化合物的多功能治疗平台的开发解决了这一局限性。该平台旨在靶向骨肉瘤细胞，同时促进骨组织修复和再生。本综述综合了集成生物活性支架（IBS）的最新进展，强调了它们在对抗骨肉瘤和促进骨再生方面的双重作用。我们还研究了IBS目前的局限性，并提出了克服这些障碍的未来研究方向。
